Glucose Transporter Type 1 Deficiency Syndrome.
- Author:
Sung Koo KIM
1
Author Information
1. Department of Pediatrics, College of Medicine, Hallym University, Seoul, Korea. kimsk@hallym.or.kr
- Publication Type:Review
- Keywords:
Glut-1 deficiency syndrome;
Epilepsy;
Hypoglycorrhachia
- MeSH:
3-O-Methylglucose;
Anticonvulsants;
Ataxia;
Blood-Brain Barrier;
Brain;
Diagnosis;
Endothelial Cells;
Epilepsy;
Erythrocytes;
Glucose Transport Proteins, Facilitative*;
Glucose Transporter Type 1*;
Glucose*;
Haploinsufficiency;
Humans;
Hypoglycemia;
Ketogenic Diet;
Lactic Acid;
Meals;
Metabolism;
Microcephaly;
Muscle Spasticity;
Ocular Motility Disorders;
Seizures
- From:
Journal of the Korean Child Neurology Society
2007;15(2):131-141
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
D-glucose is an essential fuel for metabolism in mammalian cells and the predominant fuel source for the brain. Transport of glucose across tissue barriers is mediated by stereospecific transporter proteins. Glut-1 is a major glucose transporter expressed on vascular endothelial cells comprising the blood brain barrier and is responsible for glucose entry into the brain. Impaired glucose transport across the blood brain barrier results in Glut-1 deficiency syndrome(DS). It is caused by haploinsufficiency of the blood brain barrier hexose carrier. Heterozygous mutations or hemizygosity of the GLUT-1 gene cause Glut-1 DS. It is characterized by infantile seizures refractory to anticonvulsants, developmental delay, acquired microcephaly, spasticity, ataxia, opsoclonus and other paroxysmal neurological phenomena, often occurring prior to meals. The diagnosis of Glut-1 DS is established in neurologically impaired patients with reduced cerebrospinal glucose concentration(hypoglycorrhachia) and lactate concentration in the absence of hypoglycemia. Decreased 3-O-methyl-D-glucose uptake in erythrocytes also supports the diagnosis of Glut-1 DS. Several treatment strategies have been pursued, none optimal, as it relates to the developmental encephalopahty associated with this clinical syndrome. Ketogenic diet has been effective in controlling seizures but has had little measurable effects on the associated cognitive impairments and behavioral disturbance. Current treatment is inadequate, and future studies should be directed at the mechanisms designed to upreglulate GLUT-1 expression, thereby increasing residual Glut-1 activity to 75 to 100%.
